Skip to main content

Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

The Original Article was published on 24 November 2021

Correction to: J Headache Pain 22, 141 (2021)

https://doi.org/10.1186/s10194-021-01351-2

Following the publication of the original article [1], we were notified that the x-axis labels for part B of Figure 1 were incorrect in the previous version and had accidentally been duplicated from part A.

Originally published Figure 1:

figure a

Corrected Figures:

figure b

The original article has been corrected.

Reference

  1. Nahas et al (2021) Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J Headache Pain 22:141. https://doi.org/10.1186/s10194-021-01351-2

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stephanie J. Nahas.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nahas, S.J., Naegel, S., Cohen, J.M. et al. Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J Headache Pain 23, 57 (2022). https://doi.org/10.1186/s10194-022-01423-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s10194-022-01423-x